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Background/Aims: Combination treatment consisting of hepatic arterial infusion chemotherapy with epirubicin and cisplatin 
(HAIC-EC) and systemic infusion of low-dose 5-fluorouracil (5-FU) are sometimes effective against advanced hepatocellular 
carcinoma (HCC). However, there is no effective treatment for advanced HCCs with arterioportal shunts (APS) or arteriovenous 
shunts (AVS). Methods: We investigated a response and adverse events of a new combination protocol of repeated HAIC-EC 
and percutaneous intratumoral injection chemotherapy with a mixture of recombinant interferon-gamma (IFN-γ) and 5-FU 
(PIC-IF) in patients with far-advanced HCCs with large APSs or AVSs. Results: There was a complete response (CR) for the 
large vascular shunts in all three patients and for all tumor burdens in two patients. Significant side effects were flu-like symptoms 
(grade 2) and bone marrow suppression (grade 2 or 3) after each cycle, but these were well-tolerated. Conclusions: These 
results suggest that the combination of HAIC-EC and PIC-IF is a new and promising approach for advanced HCC accompanied 
by a large APS or AVS. (Korean J Hepatol 2011;17:120-129)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the 5th most common 
malignancy worldwide and the 3rd most common cause of 
cancer mortality.
1 Because a majority of patients present at 
an advanced stage, which does not consistently respond to 
any chemotherapeutic protocols, the prognosis of HCC is 
generally very poor. Only a small proportion of cases with 
HCC diagnosed at an early stage as a result of close 
surveillance, and with serial imaging studies, could be 
eligible for and receive curative treatments, such as liver 
transplantation and surgical resection, resulting in a favorable 
long-term outcome.
2 The Barcelona Clinic Liver Cancer 
(BCLC) staging classification system, which reflects liver 
functional status and characteristic features of HCC staging, 
is a clinically useful algorithm for selecting proper management 
and predicting the prognosis of HCC patients.
2,3
The management of patients with advanced BCLC stages 
(BCLC stage C) is a complex issue, as the degree of vascular 
invasion, tumor size and number, extrahepatic metastasis, 
HCC-associated complications, liver functional reserve, and 
the performance status of the patient must be taken into 
account. Systemic chemotherapy, radiation therapy, and 
transarterial infusion chemotherapy via implantable drug 
delivery systems rarely offer survival benefits, such as select 
patients with well-preserved liver function and a good Ja Seon Kim, et al. Combined treatment of advanced HCC with shunts  121
performance status.
4 Despite a search for an effective 
multidisciplinary approach to improve outcomes, no treatment 
protocol has been developed for patients with advanced 
BCLC stages and major vascular invasions and/or extrahepatic 
metastasis. 
It was reported that repeated combination treatment 
of hepatic arterial infusion lipiodol chemotherapy with 
epirubicin and cisplatin (HAIC-EC) and systemic infusion 
of 5-fluorouracil (5-FU), a modified HAIC-EC/F protocol, 
could be beneficial with respect to the survival advantage for 
some patients with advanced HCCs and major portal vein 
invasion in comparison with control patients treated 
conservatively.
5 Another multimodality approach in which 
percutaneous ethanol injection therapy (PEIT) is used in 
addition to the same modified HAIC-EC/F protocol for far 
advanced HCCs, showed significantly better treatment 
responses than conventional trans arterial chemoembolization 
(TACE) using a mixture of lipiodol and adriamycin with 
gelfoam embolization.
6 Multimodality chemotherapeutic 
approach may be critical in the management of HCC 
patients with advanced BCLC stage and preserved liver 
function. 
Unlike metastatic liver cancers, far advanced HCCs 
frequently invade the portal or hepatic veins, sometimes 
creating vascular shunts with the hepatic artery (arterio- 
portal shunt [APS] or arterio-venous shunt [AVS]), together 
with the formation of large tumor thrombi. Current treatments 
have had little effect on the survival of patients with far 
advanced HCCs with shunts. 
In this study, we investigated the efficacy and adverse 
events of percutaneous intratumoral injection chemotherapy 
consisting of a mixture of 5-FU and recombinant interferon- 
gamma (IFN-γ; PIC-IF) in combination with HAIC-EC in 
patients far advanced HCCs with shunts. 
MATERIALS AND METHODS
Eligibility
The eligibility criteria for chemotherapy were as follows: (1) 
18-75 years of age; (2) preserved liver function (Pugh-Child 
class A and B); (3) acceptable range of thrombocytopenia 
due to portal hypertension without any other causes of bone 
marrow suppression (platelet count>50,000/mm
3 and leukocyte 
count>2,000/mm
3); (4) normal serum creatinine (Cr<1.2 
mg/dL); (5) acceptable range of hepatitis activity (alanine 
aminotransferase, [ALT]<100 IU/L); and (6) Eastern 
Cooperative Oncology Group performance status (PS) 0-2. 
The inclusion criteria of far advanced HCC features for the 
protocol were as follows: (1) TNM stage III or IV by AJCC/ 
UICC or LCSGJ classification; (2) major vascular invasion, 
such as main portal vein tumor thrombosis or main hepatic 
vein tumor thrombosis; and (3) marked vascular shunts, 
such as AVSs or APSs. Patients with HCC with extra-hepatic 
metastases at the time of initial diagnosis were also included 
if they had a marked APS or AVS. The exclusion criteria 
were as follows: (1) presence of other malignant diseases; 
(2) history of recent upper gastrointestinal bleeding; (3) 
sepsis; and (4) serious chronic disorders in other organs. We 
received informed consent in all patients treated with this 
protocol, which was approved by the Institutional Review 
Board of Bundang Jesaeng General Hospital.
Patients
Of the HCC patients admitted to our hospital between 
March 2003 and December 2009, 4 patients met the inclusion 
criteria of far advanced HCC. Because one patient is 
currently undergoing treatment, three of the four patients 
were assessed retrospectively. 
Treatment protocol
The treatment protocol, consisted of one cycle of 
HAIC-EC on day 1 and PIC-IF on day 2, repeated every 4-6 
weeks until efficacy was achieved as defined by the criteria 
of the Response Evaluation Criteria in Solid Tumors 
(RECIST). The dose of epirubicin (50 mg/m
2/session; Il 
Dong Pharmaceuticals Co. Ltd., Seoul, Korea) and cisplatin 
(60 mg/m
2/session; Dong-A Pharmaceuticals Co. Ltd., 
Seoul, Korea) for HAIC was adjusted based on age, liver 
function, and leukocyte count measured just before each 
treatment cycle. For the dose calculation equation for 
epirubicin and cisplatin, we used empirical parameters in 
each variable as follows: calculated dose=(dose per body 
surface area [BSA])×(leukocyte count/4000)×(1-[Pugh 
score-5]/10)×(1-[age-45]/100)
6; we did not consider the 
intrahepatic tumor volume parameter for the adjustment of 
dosage because all HCCs were in the advanced stage. 
Fixed doses of IFN-γ (2 million units per vial, Intermax- 
gamma; LG Life Sciences Pharmaceuticals Co. Ltd., 
Daejeon, Korea) and 5-FU (500 mg per ample; Choong Wae 
Pharmaceuticals Co. Ltd., Seoul, Korea) were used for PIC 122  The Korean Journal of Hepatology Vol. 17. No. 2, June 2011
Table 1. Profiles, responses, and outcomes of three patients with advanced HCC
Patient 1 2 3
Age/Gender/Etiologic factor 60/M/ALC 67/M/HCV 66/M/HBV
Cirrhosis/Pugh-Child class Yes/A Yes/A Yes/A
Size (maximum, cm) 12 14 12
PVTT/HVTT Vp3/Vv0 Vp3/Vv4 Vp3/Vv0
APS/AVS Yes/No Yes/No No/Yes
Extrahepatic metastasis No Lung Lung and adrenal gland
Number of HAIC-EC 10 (12)   8  12
Number of PIC-IF   10   8  13
Total dose of epirubicin (mg) 590 470 400
Total dose of cisplatin (mg) 640 505 780
Response of shunts and vascular invasion CR CR CR
Response of intrahepatic tumors CR CR CR
Response of metastatic tumors No lesions CR PD
AFP (ng/mL) (start/end of cycles) CR (>100,000/6.4) CR (2486/4.2) NR (>100,000/NC)
PIVKA-II (mAu/mL) (start/end of cycles) CR (>2000/32) CR (>2000/35) PR (>2000/199)
Survival Alive Alive Died
Survival time (months) 30.3 28.6 22.4
Recurrence of intrahepatic HCC No No No
DFI (months) 17 18 0
ALC, alcoholic; PVTT, portal vein tumor thrombosis; HVTT, hepatic vein tumor thrombosis; APS, arterio-venous shunt; AVS, 
arterio-venous shunt; HAIC-EC, hepatic arterial infusion chemotherapy with epirubicin and cisplatin; PIC-IF, percutaneous 
intratumoral injection chemotherapy with IFN-gamma and 5-FU; CR, complete response; PR, partial response; PD, progressive 
disease; NR, no response; DFI, disease-free interval.
to the far advanced HCCs (10 MU and 1500 mg per session, 
respectively). This cocktail ratio was decided by the maximum 
efficient combination, which was calculated by HCC cell line 
experiments.
For HAIC-EC, 1 liter of normal saline was administered 
intravenously before and after the transarterial angiographic 
procedure to prevent cisplatin-induced nephrotoxicity. 
Dolasetron mesylate (200 mg per tab, Anzemet, Sanofi- 
Aventis; HANDOK Pharmaceuticals Co. Ltd., Seoul, 
Korea) was used to treat nausea and vomiting following 
chemotherapy for 4 successive days. Megestrol acetate oral 
suspension (800 mg per pack, Apetrol; LG Life Sciences 
Pharmaceuticals Co. Ltd., Daejeon, Korea) was also used to 
improve appetite and quality of life. 
For PIC-IF, IFN-γ (10 million units) and 5-FU (1,500 mg) 
were mixed well just before injection via a PEIT needle (21 
gauge, 200 mm size with 3-7 holes and a closed tip) with an 
extension tube. Under ultrasonographic guidance, the needle 
tip was rapidly placed in the target area, which included 
HCC at the border invading the portal or hepatic veins or the 
inner mantle portion of the HCC. After which the syringe 
with the cocktail was injected very slowly over 10 minutes. 
The fasting state was at least 6 hours, and 50 mg of demerol 
and hydroxyzine (25 mg per tab, Ucerax; Yuhan Pharma-
ceuticals Co. Ltd., Seoul, Korea), a sedating antihistamine, 
was administered 30 minutes before the procedure as a 
premedication, and propacetamol HCl (1 g per vial, Denogan, 
Yungjin Pharmaceuticals Co. Ltd, Seoul, Korea), an anti- 
pyretic, was administered intravenously for 15 min to treat 
IFN-γ-induced flu-like reactions, such as fevers, chills and 
myalgias, immediately following the procedure. 
The length of admission was usually from 4-7 days. 
Laboratory tests were usually performed 3 times during the 
admission (before and 1 day after treatment, and prior to 
discharge). Additional laboratory tests were performed from 
7-10 days after discharge in the outpatient clinic to evaluate Ja Seon Kim, et al. Combined treatment of advanced HCC with shunts  123
Figure 1. Clinical response and changes in tumor markers after 
combination treatment with HAIC-EC and PIC-IF in patient 1. 
Complete remission of HCC was achieved after 10 cycles of treatment.
HAIC-EC, hepatic arterial infusion (lipiodol) chemotherapy with 
epirubicin and cisplatin; PIC-IF, percutaneous intratumoral injection
chemotherapy with a mixture of IFN-γ and 5-FU; HCC, hepatocellular
carcinoma.
  
  
Figure 2. Dynamic CT (A, before treatment; B, after treatment) scans showing the response to the treatment protocol in patient 1. 
Diffuse tumor thrombosis along the entire intrahepatic portal vein system (black arrow) and massive infiltrative type HCC lesion were 
markedly regressed (white arrow). Hepatic arteriography (C, before treatment; D, after treatment) showing a huge hypervascular mass 
with a large APS before treatment (arrow). Complete remission of both intrahepatic HCC lesions and massive APS was achieved 
after 10 cycles of treatment.
the degree of bone marrow suppression.
Effecacy and adverse reactions
Treatment efficacy according to the RECIST criteria was 
evaluated after at least two cycles of protocol therapy, and 
every cycle thereafter. Treatment efficacy was based on 
changes in the characteristic features of the HCC as shown 
in clinico-radiologic studies, including an alpha-fetoprotein 
(AFP) level, PIVKA-II, conventional biochemical liver 
function tests, a triphasic liver CT scan, and a hepatic 
arteriogram, which were performed during each treatment 
cycle. The radiologic features included the changes in the 
number and sizes of tumors, response pattern of vascular 
thrombosis and occlusion of shunts, together with enhancing 
patterns around the tumor nodules. 
Adverse reactions were assessed during and after each 
A B
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Figure 3. Clinical response and changes in tumor markers after 
combination treatment with HAIC-EC and PIC-IF in patient 2. 
Complete remission of intrahepatic HCC with a large shunt and 
pulmonary metastasis was achieved after six cycles of treatment. 
Elevation of tumor marker levels was observed without any 
radiologic evidence of recurrence. The serologic HCC biomarkers 
normalized after the oral administration of tegafur and uracil.
cycle of protocol therapy according to the criteria of the 
National Cancer Institute Common Toxicity Criteria (NCI-CTC; 
version 2.0).
3
RESULTS
Response and outcome
All three patients, who were AJCC-TNM stage IV, BCLC 
stage C, and Pugh-Child class A, had an objective response, 
tumor shrinkage, and disappearance of the APS or AVS. CR 
to our multimodality protocol, the combination treatment of 
HAIC-EC and PIC-IF, was obtained in two patients. The 
disease-free survivals of the two patients with CRs without 
any evidence of recurrence until the present are 28.6 months 
and 30.3 months, respectively. One patient had a CR in an 
intrahepatic HCC lesion, but progressive disease in metastatic 
lesions (lung and adrenal gland), and died of respiratory 
failure and septicemia; the survival time was 22.4 months. 
Each clinical course is described in detail below (Table 1).
Patient 1 
A 60-year-old man was admitted due to variceal bleeding. 
Dynamic CT scan showed a massive infiltrative type of 
HCC with a maximum diameter ≥12 cm and the main portal 
vein tumor thrombosis with a massive APS in the right lobe. 
The baseline blood tests were as follows: white blood cell 
count (WBC) 17,100/mm
3, hemoglobin 6.2 g/dL, platelet 
count 217,000/mm
3, albumin 2.8 g/dL, total bilirubin 1 
mg/dL, prothrombin time-INR 1.2, alkaline phosphatase 
(ALP) 488 IU/L, aspartate aminotransferase (AST) 170 IU/L, 
alanine aminotransferase (ALT) 64 IU/L, total cholesterol 
109  mg/dL, creatinine 0.9  mg/dL, AFP and PIVKA-II 
>100,000 ng/mL and >2,000 mAU/mL respectively. HBsAg 
and anti-HCV were negative. After recovery from variceal 
bleeding by ligation therapy, when the liver function 
reverted to Pugh-Child A without ascites, the protocol 
therapy of HAIC-EC and PIC-IF was started. This patient 
had a CR in both serologic HCC biomarkers and radiologic 
evaluations after 10 cycles of the treatments, and is still alive 
without any evidence of recurrence for 30 months 
(disease-free interval [DFI], 17 months) (Fig. 1, 2).
Patient 2
A 67-year-old man, who had experienced exertional 
dyspnea and chest discomfort for 1 month, was admitted for 
the treatment of advanced HCC. At the time of the initial 
evaluation, a dynamic CT scan showed a massive infiltrating 
HCC with a maximum diameter of 14 cm occupying the 
right lobe with extensive tumor thrombosis in the right 
hepatic vein, inferior vena cava, and right atrium, and the 
main portal vein tumor thrombosis with a massive APS. 
Multiple metastases were observed in both lung fields. The 
initial laboratory test showed the following: hemoglobin 15 
g/dL, WBC 5,300/mm
3, platelet 94,000/mm
3, albumin 3.9 
g/dL, total bilirubin 1.45 mg/dL, prothrombin time-INR 
1.18, ALP 1,951 IU/L, AST 118 IU/L, ALT 48 IU/L, total 
cholesterol 86 mg/dL, AFP and PIVKA-II 2,486 ng/mL and 
>2000 AU/mL, respectively. HBsAg was negative, and 
anti-HCV was positive, however quantitative HCV RNA 
(Cobas Amplicor HCV Monitor 2.0
®; Roche Diagnostics, 
Branchburg, NJ, USA) was negative. Soon after the protocol 
therapy, together with an improvement in symptoms, the 
patient showed objective responses in all lesions, including 
the intrahepatic HCC lesions, vascular invasion, and 
pulmonary metastases (Fig. 3, 4). During the follow-up, the 
AFP and PIVKA-II levels were elevated without any disease 
progression evident on radiologic evaluations. After the oral 
administration of tegafur and uracil (tegafur [100 mg], uracil 
[224 mg per 0.5 g pack], UFT-E granules, Jeil Pharmaceuticals 
Co. Ltd, Seoul Korea), both serological HCC biomarkers 
normalized again (Fig. 3). The patient is alive without any Ja Seon Kim, et al. Combined treatment of advanced HCC with shunts  125
  
  
Figure 4. Dynamic CT (A, before treatment; B, after treatment) scans showing the response to the treatment protocol in patient 2. 
An ill-defined huge mass mainly involving the right lobe (white arrow) and tumor thrombosis along the right portal system (black 
arrow) and inferior vena cava were markedly decreased after treatment. Pulmonary metastatic lesions had also completely disappeared 
(dotted arrow). Hepatic arteriography (C, before treatment; D, after treatment) showed an ill-defined huge mass mainly involving the 
right lobe and tumor thrombosis along the right portal system and inferior vena cava, together with a large APS at the time of initial 
treatment. All of the lesions had markedly improved after the treatment.
evidence of recurrence after 28 months (DFI, 18 months).
Patient 3
A 66-year-old man who had anorexia and nausea for 1 
month was found to have liver cirrhosis and far advanced 
HCC during an evaluation. The initial dynamic CT scan 
showed a massive infiltrating HCC with a maximum 
diameter of 12 cm occupying the right lobe, and complicated 
by a turmor thrombosis in the main hepatic vein with a large 
AVS. Small pulmonary metastatic lesions were also 
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Figure 5. Clinical response and changes in tumor markers after 
combination treatment with HAIC-EC and PIC-IF in patient 3. 
Intrahepatic HCC lesions with a large AVS showed a complete 
response to the treatment protocol, but extrahepatic metastatic 
lesions showed only a partial response early in the treatment 
course. However, elevation of the AFP and PIVKA-II levels and 
multiple metastases in both lungs and adrenal gland were 
aggravated without intrahepatic recurrence of HCC late in the 
treatment course.
identified. The initial laboratory tests were as follows: 
hemoglobin 15.7 g/dL, WBC 5,000/mm
3, platelet 128,000/mm
3, 
albumin, 4.1 g/dL, total bilirubin 1.0 mg/dL, prothrombin 
time-INR 1.21, ALP 254 IU/L, AST 242 IU/L, ALT 60 
IU/L, total cholesterol 190 mg/dL, AFP and PIVKA-II 
192,320 ng/mL and >2000 AU/mL, respectively. HBsAg 
was positive, HBeAg and HBV DNA (Amplicor HBV 
Monitor
®; Roche Molecular System, Pleasanton, CA, USA) 
were negative, and anti-HCV was negative. After the 
protocol therapy, together with the improvement in symptoms, 
the patient showed objective responses completely in the 
intra- hepatic HCC lesions, vascular invasion, and AVS by 
radiologic evaluations, and also partial improvement in the 
extra-hepatic lesions based on AFP and PIVKA-II tests (Fig. 
5, 6). However, on serial testing, the levels of serologic HCC 
biomarkers rose again, and multiple metastases to both lung 
fields and the right adrenal gland occurred rapidly, in spite of 
repeated courses of chemotherapy (Fig. 5). The patient died 
of respiratory failure with septicemia 22 months after 
registration.
Adverse events
HAIC-EC-associated side effects were observed in all 3 
patients (NCI-CTC grade 1 or 2 grade nausea developed 
during the admission period and grade 2 or 3 leucopenia 
developed 7-10 days after discharge). PIC-IF-associated 
side effects were observed in all 3 patients (grade 2 or 3 
flu-like symptoms developed 20-30 minutes after the procedure). 
All side effects were transient and well-tolerated. However, 
there was a tendency for the degree of bone marrow 
suppression to be progressively aggravated by the repeated 
treatments, but no greater than toxicity grade 3. Neither 
NCI-CTC grade 4 complications nor deterioration in liver 
and/or renal function developed during repeat protocol 
therapy.
DISCUSSION
In patients with far advanced HCC complicated by major 
portal vein tumor thrombosis, the prognosis is dismal, and if 
not treated, the overall survival is 3.5 months.
5 Even if 
treated aggressively by various protocols of hepatic arterial 
infusion chemotherapy using a combination of 5-FU and 
cisplatin, the objective response rates are about 20% without 
any CRs; the median survival of patients with objective 
response is only 8-14 months, and the 2-year survival is ≤
25%.
7,8 This survival is much shorter than that of the entire 
HCC cohort, in which the 1-and 3-year survival is 58% and 
29%, respectively.
3 A chemotherapy protocol using combined 
transarterial epirubicin (50 mg/m
2) plus cisplatin (60 mg/m
2) 
chemo-lipiodolization and systemic 5-FU (200 mg/m
2) 
chemo-infusion (ECF regimen) at monthly intervals also 
showed similar results to the combination protocol of 5-FU 
and cisplatin, although significantly better than the patients 
treated conservatively (objective response, 21.3%; and 
overall survival, 8.7 months).
5 These findings suggest that 
major occlusion of the portal vein invaded by HCC 
determines resistance to treatment as well as decreased liver 
function, increased MELD score, and poor performance 
status. Together with portal vein tumor thrombosis, the 
occurrence of APS or AVS thwarts the strength of will for 
further treatment of HCC. 
However, advances in techniques have made it possible to 
approach the treatment of HCC patients with complicated 
findings. For example, transarterial embolization (TAE) 
using steel coils successfully treated 3 patients with HCC 
with massive APS.
9 TACE during the corresponding portal 
vein occlusion in HCC patients with marked APS also Ja Seon Kim, et al. Combined treatment of advanced HCC with shunts  127
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Figure 6. MRI and dynamic CT (A, before treatment; B, after treatment) scans showing the response to the treatment protocol in 
patient 3. A massive HCC in the right hepatic lobe with right portal vein invasion and multiple lung metastases were noted, but 
initial MRI revealed no lesions in the adrenal gland. After the treatment protocol the intrahepatic tumor lesions were markedly improved 
(white arrow), but the left adrenal metastasis (dotted arrow) and pulmonary metastatic nodules (black arrow) were aggravated. Hepatic 
arteriography (C, before treatment; D, after treatment) showed a huge hypervascular HCC in the right hepatic lobe and a large AVS 
(white arrow). Both the HCC lesion and AVS shunt had disappeared after the treatment protocol.128  The Korean Journal of Hepatology Vol. 17. No. 2, June 2011
showed better treatment responses than shunt embolization 
with the use of coils and/or gelatin-sponge particles.
10
In the current study we developed a new multimodal 
protocol of PIC-IF in combination with HAIC-EC for the 
treatment of advanced HCCs. A key component in this 
protocol is the direct injection of a cocktail of IFN-γ and 
5-FU into the marginal part of the tumor by the same 
technique as PEIT, by which parts of cancer cells are 
transiently exposed to very high concentrations of an anti- 
cancer cocktail. Such intratumoral injection of chemothe-
rapeutic agents can provide a high concentration of drug to 
the tumors much more conveniently and effectively than 
intra-arterial infusion while reducing systemic exposure. 
The intratumoral injection method has been more frequently 
adapted in antitumor immunotherapy studies to induce 
immunologic responses locoregionally. Intratumoral injection 
of recombinant interleukin-12 induces very high concentration 
of IFN-γ from tumor-infiltrating Th1 cells.
11 
IFN-γ-inducible protein 10 (IP-10), a potent inhibitor of 
tumor angiogenesis, in combination with gemcitabine has 
synergistic effects on tumors by inhibiting the proliferation 
of endothelial cells, inducing the apoptosis of tumor cells, 
and recruiting lymphocytes to tumors in murine models.
12 
Otherwise, CD4(+) T cells play a pivotal role in controlling 
early tumor development through inhibition of tumor 
angiogenesis which is IFN-γ-dependent. IFN-γ-dependent 
inhibition of tumor angiogenesis by CD4(+) T cells requires 
tumor responsiveness to IFN-γ.
13
Because non-responders to chemotherapy usually have a 
significantly higher percentage of Th2 cells, which down- 
regulate antitumor immunity, than the responders both 
before and after chemotherapy, inhibition of an increase of 
Th2 cells might be important for the efficacy of transarterial 
combination chemotherapy in advanced HCCs with cirrhosis.
14 
We reasoned that locoregional adjuvant injection of 
recombinant IFN-γ might modulate Th1/Th2 balance of the 
tumor to favor an anti-tumor response.
Furthermore, IFN-γ synergistically enhances anti-cancer 
efficacy of chemotherapeutic agents, such as 5-FU, mitomycin-C 
and cisplatin.
15,16 Suggested mechanisms are the inhibition 
of MDR P-glycoprotein expression and up-regulation of 
caspase-8.
17,18 As another mechanism, while HBV expression 
in HCC cell lines shows drug resistance against 5-FU, IFN-γ 
treatment modulates this type of chemoresistance to be more 
chemosensitive by inhibition of HBV-related NF-kappa B 
activation.
19 
In our protocol, an anti-cancer cocktail consisting of IFN-
γ and 5-FU was injected directly into the periphery of the 
tumor and/or a root part of the vascular invasion, under the 
assumption that 5-FU modulates IFN receptor expression,
20 
and locoregional IFN-γ plays a pivotal role in establishing 
the anti-tumor immune response and additive effects of 
chemotherapeutic agents. Although our study included only 
three patients, the results suggest the possibility that this 
type of multimodal protocol therapy may be a promising 
approach to the treatment of advanced HCCs with or without 
vascular invasions or large shunts.
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